Targeted therapy for ovarian cancer – case report

05/2018

MUDr. Mária Zvariková

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

SUMMARY

Treatment of epithelial ovarian cancer is historically based on surgery and platinum doublet chemotherapy and is associated with high risk of relapse and poor prognosis in recurrent disease. Innovative treatment with PARP inhibitors has demonstrated an outstanding activity in epithelial ovarian cancer and is currently changing clinical practice in patients with BRCA mutation in genes.

KEY WORDS

ovarian cancer, PARP inhibitor, olaparib